Broadcast Date: 
  • Time: 

There is surging interest (and competition) in the proteomics industry, reminiscent of the state of NGS and genomics a decade ago. While mass spectrometry (MS) technologies remain the tried-and-true method for analyzing the proteome, established MS companies have been joined by a powerful set of emerging technologies offering the ability to survey more proteins, with higher sensitivity, specificity and greater ease. Indeed, some companies aim to detect disease using protein measurements. This is providing researchers who need to assess the proteome choices that they simply did not have before.

On this episode of GEN Live, we will talk about proteomics—as a tool and as a field. Where is it now and what type of research is proteomics enabling? We will also discuss the latest technologies and instruments in this space. What will it take for these new companies to compete?

A live Q&A session followed the discussion, offering a chance to pose questions to our expert panelists.

Ben Neely
Ben Neely, PhD
Research Chemist
National Institute of Standards and Technology
Lindsay Pino
Lindsay Pino, PhD
Co-founder and CTO
Talus Bio